Youmna Kfoury

Mesenchymal Cell Contributions to the Stem Cell Niche

Mesenchymal stromal cells (MSCs) are heterogeneous and primitive cells discovered first in the bone marrow (BM). They have putative roles in maintaining tissue homeostasis and are increasingly recognized as components of stem cell niches, which are best defined in the blood. The absence of in vivo MSC markers has limited our ability to track their behavior in vivo and draw comparisons with in vitro observations. Here we review the historical background of BM-MSCs, advances made in their prospective isolation, their developmental origin and contribution to maintaining subsets of hematopoietic cells, and how mesenchymal cells contribute to other stem cell niches.

Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma

HTLV-I associated adult T-cell leukemia (ATL) and HTLV-I-negative peripheral T-cell lymphomas are associated with poor prognosis. Using pharmacological concentrations of the proteasome inhibitor PS-341, we demonstrate inhibition of cell proliferation and induction of apoptosis in fresh ATL cells, HTLV-I transformed and HTLV-I-negative malignant T cells, while normal resting or activated T lymphocytes were resistant. Combination of PS-341 and doxorubicin or etoposide resulted in an additive growth inhibition. In HTLV-I-negative malignant cells, PS-341 treatment significantly downregulated the antiapoptotic protein X-IAP and to a lesser extent c-IAP-1 and bcl-XL and resulted in caspase-dependent apoptosis. In HTLV-I transformed cells, the inhibition of the proteasomal degradation of Tax by PS-341 likely explains the relative protection of HTLV-I infected cells against caspase-dependent apoptosis. PS-341 treatment of these cells stabilized IκBα, IκBβ, IκBɛ, p21, p27 and p53 proteins and selectively inhibited Rel-A DNA binding NF-κB complexes. In both HTLV-I-positive and -negative cells, PS-341 treatment induced ceramide accumulation that correlated with apoptosis. We conclude that PS-341 affects multiple pathways critical for the survival of HTLV-I-positive and -negative malignant T cells supporting a potential therapeutic role for PS-341 in both ATL and HTLV-I-negative T-cell lymphomas, whether alone or in combination with chemotherapy.

Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia

Treatment with a combination of interferon-α and arsenic trioxide ablates leukemia-initiating activity before reducing primary tumor bulk in a murine model of adult T cell leukemia.

Ubiquitylated Tax targets and binds the IKK signalosome at the centrosome

Constitutive activation of the NF-κB pathway by the Tax oncoprotein plays a crucial role in the proliferation and transformation of HTLV-I infected T lymphocytes. We have previously shown that Tax ubiquitylation on C-terminal lysines is critical for binding of Tax to IκB kinase (IKK) and its subsequent activation. Here, we report that ubiquitylated Tax is not associated with active cytosolic IKK subunits, but binds endogenous IKK-α, -β, -γ, targeting them to the centrosome. K63-ubiquitylated Tax colocalizes at the centrosome with IKK-γ, while K48-ubiquitylated Tax is stabilized upon proteasome inhibition. Altogether, these results support a model in which K63-ubiquitylated Tax activates IKK in a centrosome-associated signalosome, leading to the production of Tax-free active cytoplasmic IKK. These observations highlight an unsuspected link between Tax-induced IKK activation and the centrosome.

Hematopoietic Stem Cell Niche in Health and Disease

Regulation of stem cells in adult tissues is a key determinant of how well an organism can respond to the stresses of physiological challenge and disease. This is particularly true of the hematopoietic system, where demands on host defenses can call for an acute increase in cell production. Hematopoietic stem cells receive the regulatory signals for cell production in adult mammals in the bone marrow, a tissue with higher-order architectural and functional organization than previously appreciated. Here, we review the data defining particular structural components and heterologous cells in the bone marrow that participate in hematopoietic stem cell function. Further, we explore the case for stromal-hematopoietic cell interactions contributing to neoplastic myeloid disease. As the hematopoietic regulatory networks in the bone marrow are revealed, it is anticipated that strategies will emerge for how to enhance or inhibit production of specific blood cells. In that way, the control of hematopoiesis will enter the domain of therapies to modulate broad aspects of hematopoiesis, both normal and malignant.

Tax ubiquitylation and SUMOylation control the dynamic shuttling of Tax and NEMO between Ubc9 nuclear bodies and the centrosome

The HTLV-I oncoprotein Tax is critical for T cell transformation, acting mainly through NEMO binding and subsequent NFB activation. Tax localizes to Tax nuclear bodies and to the centrosome and is subjected to ubiquitylation and SUMOylation that are both necessary for complete transcriptional activation. By using the photoconvertible fluorophore Dendra-2 coupled with live video confocal microscopy, we show for the first time that the same Tax molecule shuttles among Tax nuclear bodies and between these nuclear bodies and the centrosome depending on its post-translational modifications. Ubiquitylation targets Tax to nuclear bodies to which NEMO is recruited and subsequently SUMOylated. We also demonstrate that Tax nuclear bodies contain the SUMOylation machinery including SUMO and the SUMO conjugating enzyme Ubc9, strongly suggesting that these nuclear bodies represent sites of active SUMOylation. Finally, both ubiquitylation and SUMOylation of Tax control NEMO targeting to the centrosome. Altogether, we are proposing a model where both ubiquitylation and SUMOylation of Tax control the shuttling of Tax and NEMO between the cytoplasmic and nuclear compartments.

Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin

Hematopoietic stem cell transplantation (HSCT) offers curative therapy for patients with hemoglobinopathies, congenital immunodeficiencies, and other conditions, possibly including AIDS. Autologous HSCT using genetically corrected cells would avoid the risk of graft-versus-host disease (GVHD), but the genotoxicity of conditioning remains a substantial barrier to the development of this approach. Here we report an internalizing immunotoxin targeting the hematopoietic-cell-restricted CD45 receptor that effectively conditions immunocompetent mice. A single dose of the immunotoxin, CD45–saporin (SAP), enabled efficient (>90%) engraftment of donor cells and full correction of a sickle-cell anemia model. In contrast to irradiation, CD45–SAP completely avoided neutropenia and anemia, spared bone marrow and thymic niches, enabling rapid recovery of T and B cells, preserved anti-fungal immunity, and had minimal overall toxicity. This non-genotoxic conditioning method may provide an attractive alternative to current conditioning regimens for HSCT in the treatment of non-malignant blood diseases.

Proapoptotic regimes for HTLV-I-transformed cells : targeting Tax and the NF-κB pathway

Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016-S0305-7372(03)00081-1; Arnulf B, 2002, BLOOD, V100, P4129, DOI 10.1182-blood-2001-12-0372; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146-annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146-annurev.immunol.14.1.649; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126-science.2843985; Bangham CRM, 2000, CURR OPIN IMMUNOL, V12, P397, DOI 10.1016-S0952-7915(00)00107-2; Bazarbachi A, 1999, BLOOD, V93, P278; Bazarbachi A, 2001, VIRUS RES, V78, P79, DOI 10.1016-S0168-1702(01)00286-6; Bazarbachi A, 2004, CANCER RES, V64, P2039, DOI 10.1158-0008-5472.CAN-03-2390; Bazarbachi A, 2004, LANCET ONCOL, V5, P664, DOI 10.1016-S1470-2045(04)01608-0; BERAUD C, 1996, J ACQ IMMUN DEF SYND, V13, P76; Bex F, 1998, MOL CELL BIOL, V18, P2392; Bex F, 1997, J VIROL, V71, P3484; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084-jem.179.3.901; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006-viro.1997.8509; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128-JVI.74.5.2351-2364.2000; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; Cascio P, 2002, EMBO J, V21, P2636, DOI 10.1093-emboj-21.11.2636; Chen GQ, 1996, BLOOD, V88, P1052; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016-S0092-8674(00)81064-8; Chiari E, 2004, J VIROL, V78, P11823, DOI 10.1128-JVI.78.21.11823-11832.2004; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074-jbc.273.26.15891; Ciechanover A, 2004, TRENDS CELL BIOL, V14, P103, DOI 10.1016-j.tcb.2004.01.004; Dewan MZ, 2003, J VIROL, V77, P5286, DOI 10.1128-JVI.77.9.5286-5294.2003; El-Sabban ME, 2002, BLOOD, V99, P3383, DOI 10.1182-blood.V99.9.3383; El-Sabban ME, 2000, BLOOD, V96, P2849; Fu DX, 2003, J BIOL CHEM, V278, P1487, DOI 10.1074-jbc.M210631200; Gabet AS, 2003, ONCOGENE, V22, P3734, DOI 10.1038-sj.onc.1206468; GESSAIN A, 1985, LANCET, V2, P407; Gessain A, 1996, ADV VIRUS RES, V47, P377, DOI 10.1016-S0065-3527(08)60740-X; Good LF, 1996, J VIROL, V70, P2730; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073-pnas.86.9.3351; Harhaj EW, 1998, J BIOL CHEM, V273, P25185, DOI 10.1074-jbc.273.39.25185; Hemelaar J, 2001, J VIROL, V75, P11106, DOI 10.1128-JVI.75.22.11106-11115.2001; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016-0092-8674(92)90083-O; Hermine O, 2004, HEMATOL J, V5, P130, DOI 10.1038-sj.thj.6200374; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146-annurev.biochem.67.1.425; HINUMA Y, 1982, GAN TO KAGAKU RYOHO, V8, P1313; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073-pnas.91.9.3584; HIRAI H, 1992, ONCOGENE, V7, P1737; Huang GJ, 2002, FEBS LETT, V531, P494, DOI 10.1016-S0014-5793(02)03590-1; Ikeda K, 1999, INT J CANCER, V82, P599, DOI 10.1002-(SICI)1097-0215(19990812)82:4599

Human T Cell Leukemia Virus Type 2 Tax-Mediated NF-κB Activation Involves a Mechanism Independent of Tax Conjugation to Ubiquitin and SUMO

ABSTRACT Permanent activation of the NF-κB pathway by the human T cell leukemia virus type 1 (HTLV-1) Tax (Tax1) viral transactivator is a key event in the process of HTLV-1-induced T lymphocyte immortalization and leukemogenesis. Although encoding a Tax transactivator (Tax2) that activates the canonical NF-κB pathway, HTLV-2 does not cause leukemia. These distinct pathological outcomes might be related, at least in part, to distinct NF-κB activation mechanisms. Tax1 has been shown to be both ubiquitinated and SUMOylated, and these two modifications were originally proposed to be required for Tax1-mediated NF-κB activation. Tax1 ubiquitination allows recruitment of the IKK-γ/NEMO regulatory subunit of the IKK complex together with Tax1 into centrosome/Golgi-associated cytoplasmic structures, followed by activation of the IKK complex and RelA/p65 nuclear translocation. Herein, we compared the ubiquitination, SUMOylation, and acetylation patterns of Tax2 and Tax1. We show that, in contrast to Tax1, Tax2 conjugation to endogenous ubiquitin and SUMO is barely detectable while both proteins are acetylated. Importantly, Tax2 is neither polyubiquitinated on lysine residues nor ubiquitinated on its N-terminal residue. Consistent with these observations, Tax2 conjugation to ubiquitin and Tax2-mediated NF-κB activation is not affected by overexpression of the E2 conjugating enzyme Ubc13. We further demonstrate that a nonubiquitinable, non-SUMOylable, and nonacetylable Tax2 mutant retains a significant ability to activate transcription from a NF-κB-dependent promoter after partial activation of the IKK complex and induction of RelA/p65 nuclear translocation. Finally, we also show that Tax2 does not interact with TRAF6, a protein that was shown to positively regulate Tax1-mediated activation of the NF-κB pathway.

EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I–associated adult T-cell leukemia/lymphoma

Imiquimod is an immune response modifier currently used as a topical treatment of genital warts, basal cell carcinoma, cutaneous metastasis of malignant melanoma, and vascular tumors. We developed more efficient killers from the same family of compounds that can induce apoptosis without the prominent pro-inflammatory response associated with imiquimod. Among these new products, tk;4EAPB0203, a member of the imidazo[1,2-a]quinoxalines, exhibits an important cytotoxic activity in vitro. HTLV-I-associated adult T-cell leukemia (ATL) and HTLV-I-negative peripheral T-cell lymphomas are associated with poor prognosis. Using potentially achievable concentrations of EAPB0203, we demonstrate inhibition of cell proliferation, G2/M cell- cycle arrest, and induction of apoptosis in HTLV-I-transformed and HTLV-I-negative malignant T cells and fresh ATL cells, whereas normal resting or activated T lymphocytes were resistant. EAPB0203 treatment significantly down-regulated the antiapoptotic proteins c-IAP-1 and Bcl-XL and resulted in a significant loss of mitochondrial membrane potential, cytoplasmic release of cytochrome c, and caspase-dependent apoptosis. Moreover, in HTLV-I-transformed cells only, EAPB0203 treatment stabilized p21 and p53 proteins but had no effect on NF-kappaB activation. These results support a potential therapeutic role for EAPB0203 in ATL and HTLV-I-negative T-cell lymphomas, either as a systemic or topical therapy for skin lesions.